tirzepatide mash fda for Metabolic Dysfunction–Associated Steatohepatitis (MASH) & Uptick in GLP1 Use FDA Approves Wegovy for MASH
Description
GLP-1 from Enhance.MD
The primary endpoints were device- and/or procedure-related major adverse events (MAEs) within 30 days post-procedure and changes in HbA1c at 6 months
Survey shows links to lower substance use and better impulse control.
Weight regain after stopping semaglutide typically begins within weeks to months, with most patients returning to baseline weight within 6-12 months
Tirzepatide works best when combined with personalized nutrition guidance, physical activity, and healthy lifestyle habits
